RESUMEN
[Abstract ] CHD1L is a newly identified oncogene located at Chr 1q21,its oncogenic role in tumorigenesis is through unleashed cell proliferation, G1/S transition, inhibition of apoptosis and Chromatin instability .It is an independent biomarker that can affect tumour′s process, prognosis and survival rate.The underlying mechanisms of CHD1L activation may disrupt the cell death program via binding the apoptotic protein Nur77 or exterting relevant function by mediate CHD 1L′s target genes (ARHGEF9, TCTP, SPOCK1, and NTKL) .This paper mainly introduces its oncogenic role and research progress of related molecular mechanism .
RESUMEN
BACKGROUND: The gene for chromodomain helicase/ATPase DNA binding protein 1-like (CHD1L) was recently identified as a target oncogene within the 1q21 amplicon, which occurs in 46% to 86% of primary hepatocellular carcinoma (HCC) cases. However, the prognostic significance of CHD1L in HCC remains uncertain. In this study, we investigated the roles of CHD1L in the prognosis of HCC. METHODS: We investigated the expressions of CHD1L in tumor tissue microarrays of 281 primary HCC patients who underwent surgical resection using immunohistochemistry. Prognostic factors of HCC were examined by univariate and multivariate analyses. The median follow-up period was 75.6 months. RESULTS: CHD1L expression was observed in 48 of the 281 HCCs (17.1%). CHD1L expression was associated with a younger age (p=0.033), higher Edmondson grade (p=0.019), microvascular invasion (p<0.001), major portal vein invasion (p=0.037), higher American Joint Committee on Cancer T stage (p=0.001), lower albumin level (p=0.047), and higher alpha-fetoprotein level (p=0.002). Multivariate analyses revealed that CHD1L expression (p=0.027), Edmondson grade III (p=0.034), and higher Barcelona Clinic Liver Cancer stage (p<0.001) were independent predictors of shorter disease-free survival. CONCLUSIONS: CHD1L expression might be a prognostic marker of shorter disease-free survival in HCC patients after surgical resection.